期刊文献+

老年急性髓样白血病的治疗进展

下载PDF
导出
摘要 急性髓样白血病(acute myeloid leukemia,AML)是一种血液系统恶性疾病,其特征是髓系前体的克隆性扩增,在参与自我更新、增殖和分化的过程中获得遗传异常。AML在老年群体中发病率更高,预后更差。目前,对于AML发病机制的研究取得了长足进展,但由于老年患者对化疗耐受力差,治疗选择常受限。近年来,针对AML的新疗法逐渐被开发,老年AML的治疗方案逐渐增多,包括对细胞毒性化学疗法、表观遗传靶向药物以及免疫疗法等。同时,不同作用机制药物的联合应用也不断被探索,老年AML患者的治疗及预后有望得到改善。
出处 《临床荟萃》 CAS 2023年第10期954-960,共7页 Clinical Focus
  • 相关文献

参考文献6

二级参考文献35

  • 1Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30(21 ):2670-2677.
  • 2Yamada K, Furusawa S, Saito K, et al. Concttrrent use of granu- locyte colony-stimulating factor with low-dose cytosine arabino- side and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia,1995, 9 ( 1 ): 10-14.
  • 3Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommen- dations of the International Working Group for diagnosis, stan- dardization of response criteria, treatment outcomes, and report- ing standards for therapeutic trials in acute myeloid leukemia EJ]. J Clin Oncol, 2003, 21 (24):4642-4649.
  • 4Cheson BD, Greenberg PL, Bennett JM, et al. Clinical applica- tion and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425.
  • 5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes: the alternative dosing for out- patient treatment (ADOPT) trial [J]. J Clin Oncol, 2009, 27(23):3842-3848.
  • 6Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia [J]. Am J Hematol, 2009, 84 (9) :599-600.
  • 7Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study ofepigen- etic priming with decitabine prior to standard induction chemo- therapy for patients with AML[J]. Blood, 2011, 118(6):1472- 1480.
  • 8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J]. Ann Hematol, 2012, 91 (12): 1879-1886.
  • 9Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines IJ]. Clin Cancer Res, 2007, 13( 14):4225-4232.
  • 10Qian S, Duan L. Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes [G]. 12^th International Symposium on Myelodysplastie Syndromes. Berlin, Germany: Leukemia Research, 2013: S 152-S 153.

共引文献137

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部